Last updated: February 20, 2026
What Is the Product Associated With NDC 69680-0168?
NDC 69680-0168 corresponds to Irazole (rimegepant) 75 mg tablets. It is marketed primarily for the treatment of acute migraine attacks and belongs to the class of gepants, a newer oral medication class targeting calcitonin gene-related peptide (CGRP).
Market Size and Demand Drivers
Current Market Landscape
The global migraine treatment market was valued at approximately $4.7 billion in 2022, with oral CGRP receptor antagonists representing a growing subset. Rimegepant competes with drugs like ubrogepant and earlier therapies such as triptans.
Analysts' Growth Forecast
- Compound annual growth rate (CAGR): 8.2% (2023–2028).
- Market projections attribute growth partly to increased awareness, expanded indications, and approval of oral CGRP antagonists.
Key Market Segments
- Acute Migraine Treatment (primary target): Expected to hold over 80% of the market share.
- Maintenance Therapy (under evaluation): Emerging segment with potential for future expansion.
- Geographical Reach: North America dominates, accounting for ~65% of sales, followed by Europe (~20%) and Asia-Pacific (~15%).
Competitive Landscape and Market Share
Major Competitors
| Drug Name |
Class |
Market Share (2022) |
Price Range (per dose) |
Approval Date |
| Rimegepant (NDC 69680-0168) |
Gepant |
35% |
$50–$70 |
July 2020 (FDA) |
| Ubrogepant |
Gepant |
25% |
$45–$65 |
May 2019 (FDA) |
| Sumatriptan |
Triptan |
20% |
$10–$20 |
1992 (FDA) |
| Others |
- |
20% |
Varies |
- |
Patent and exclusivity status
- Rimegepant's patent expiration is projected for 2032.
- Limited biosimilar entries as of 2023, with one biosimilar in late-stage development.
Pricing Structure and Trends
Historical Pricing
- Initial wholesale acquisition cost (WAC): roughly $55 per tablet.
- Average retail price: approximately $65–$70 per dose in the U.S.
Current Price Dynamics
- Prices have remained stable over the past 12 months, with potential slight downward pressure due to increasing competition and patent expiration forecasts.
- Reimbursement policies favor branded drugs, but insurers are increasingly adopting step therapy protocols that can restrict access.
Key Factors Impacting Prices
- Insurance Coverage: High co-pays may limit patient access.
- Regulatory Decisions: Label expansions could influence pricing strategies.
- Market Entry of Biosimilars: Limited, but potential for future price declines.
Price Projections (2023–2028)
| Year |
Estimated Average Price per Dose |
Rationale |
| 2023 |
$65 |
Current stable market with limited biosimilar competition. |
| 2024 |
$63 |
Slight downward trend as biosdenotes or generics approach approval. |
| 2025 |
$60 |
Increased biosimilar entries may influence price reductions. |
| 2026 |
$58 |
Market consolidation and price competition intensify. |
| 2027 |
$55 |
Price stabilizes near manufacturing cost, with volume growth compensating. |
| 2028 |
$52 |
Further generic/biosimilar penetration leading to price depression. |
Regulatory and Market Access Impact
- Pending label expansions could broaden use, stabilizing income.
- Insurance negotiations will influence net pricing.
- Potential biosimilar approvals could lower prices by up to 20-30%.
Key Takeaways
- NDC 69680-0168 (rimegepant) commands a premium pricing tier relative to older therapies.
- The market expects consolidated growth driven by increased prescription volume and expanded indications.
- Competition from biosimilars and generics will exert downward pressure over the next 5 years.
- Pricing stability depends heavily on regulatory decisions and payer policies.
5 FAQs
1. How does rimegepant compare to other migraine drugs in terms of price?
It is priced significantly higher than triptans (e.g., sumatriptan), reflecting its newer development status, targeted mechanism, and convenience.
2. What is the likelihood of biosimilars affecting the price?
Biosimilar development is progressing slowly due to the complexities of biologic manufacturing, but approvals could occur by 2026–2028, potentially reducing prices.
3. How will insurance coverage influence future pricing?
Insurance policies favor preferred formulary placements, which can restrict access to higher-priced branded drugs, pressuring manufacturers to adjust prices.
4. Are there any upcoming patent expirations for rimegepant?
Patent expiration is projected for 2032. Early biosimilar or generic competition is unlikely before 2026.
5. What is the potential for new indications to impact pricing?
Additional approved uses could introduce new pricing dynamics, but they generally do not alter the existing price structure significantly.
References
- MarketsandMarkets. (2023). Migraine drugs market forecast. https://www.marketsandmarkets.com/
- IQVIA. (2022). U.S. Prescription Drug Data. IQVIA Institute.
- FDA. (2020). Rimegepant approval letter. https://www.fda.gov/
- Evaluate Pharma. (2022). 2022 Global Forecast Report.
- Lazard. (2023). Biotech and biosimilar market update. https://www.lazard.com/
[1] APA citation style for all sources used.
